The earnings call highlighted strong financial performance and growth for VYVGART, with significant pipeline expansion and positive real-world impacts. However, there were challenges related to gross to net adjustments, supply issues in China, increased cost of sales, and monitoring of a potential safety signal. Overall, the positive aspects, including exceptional growth and innovation, outweigh the challenges.

Company Guidance -

Q3 2025

During the call, Argenx provided comprehensive guidance on its financial and operational achievements. The company reported a significant year-over-year growth of 97% in VYVGART sales across its approved indications, with 15,000 patients now on treatment globally. Financially, Argenx achieved a total operating income of $967 million in Q2 2025, with $949 million from product net sales. Regionally, the U.S. contributed $802 million, Japan $52 million, and other markets $83 million. The company highlighted a robust pipeline with three Phase III assets and a strategic focus on expanding VYVGART's potential while advancing new molecules. Their cash position strengthened to $3.9 billion, underscoring a solid financial foundation to support future growth and innovation.

Exceptional Growth for VYVGART

VYVGART achieved a 97% year-over-year growth across all approved indications with 15,000 patients globally being treated, including 2,500 CIDP patients just one year into the launch.

Strong Financial Performance

Total operating income in Q2 2025 was $967 million, reflecting a 97% growth since last year, with a quarter-over-quarter growth of 19% in product net sales.

Pipeline Expansion and Innovation

Initiated multiple registrational trials in large market opportunities and advanced 4 new molecules into the pipeline, including ARGX-119 and collaboration with Unnatural Products for AI-driven discovery.

Global Market Expansion

Product net sales grew in all global markets except China, with non-U.S. markets representing more than 15% of global product net sales.

Positive Real-World Impact

Positive patient stories, such as improved quality of life for CIDP patients using VYVGART Hytrulo prefilled syringe, highlight the real-world impact of the treatment.

Argenx Se (ARGX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ARGX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	4.56 / -	1.39	―	―	―
Jul 31, 2025	2025 (Q2)	3.09 / 3.74	0.45	731.11% (+3.29)
May 08, 2025	2025 (Q1)	2.42 / 2.58	-1.04	348.08% (+3.62)
Feb 27, 2025	2024 (Q4)	1.71 / 11.79	-1.68	801.79% (+13.47)
Oct 31, 2024	2024 (Q3)	0.15 / 1.39	-1.25	211.20% (+2.64)
Jul 25, 2024	2024 (Q2)	-0.90 / 0.45	-1.69	126.63% (+2.14)
May 09, 2024	2024 (Q1)	-0.77 / -1.04	-0.52	-100.00% (-0.52)
Feb 29, 2024	2023 (Q4)	-1.32 / -1.68	-0.7	-140.00% (-0.98)
Oct 31, 2023	2023 (Q3)	-1.45 / -1.25	-4.26	70.66% (+3.01)
Jul 27, 2023	2023 (Q2)	-1.71 / -1.69	-3.81	55.64% (+2.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ARGX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$598.89	$670.33	+11.93%
May 08, 2025	$622.93	$569.12	-8.64%
Feb 27, 2025	$623.02	$624.70	+0.27%
Oct 31, 2024	$551.71	$586.30	+6.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Argenx Se (ARGX) report earnings?

Argenx Se (ARGX) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is Argenx Se (ARGX) earnings time?

Argenx Se (ARGX) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ARGX EPS forecast?

ARGX EPS forecast for the fiscal quarter 2025 (Q3) is 4.56.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing